Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noad051 ↗Kurz gefasst
Leserbrief in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Jan-Michael Werner und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
The prospective phase 2 REGOMA trial suggested considerable survival benefits of the oral multikinase inhibitor regorafenib for treating patients with recurrent glioblastoma.1 For response assessment, the criteria of the Response Assessment in Neuro-Oncology (RANO) Working Group for anatomical MRI are used in daily routine and clinical trials.2 Nevertheless, anatomical MRI may present inconclusive findings related to its limited specificity for neoplastic tissue.3,4 Accordingly, similar to glioma patients treated with standard chemoradiation using alkylating agents, equivocal MRI findings were also reported in glioma patients treated with regorafenib at recurrence.5–7 It has been suggested that amino acid PET using O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) or 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA) may help to identify treatment-related changes such as pseudoresponse or pseudoprogression, and to assess response to regorafenib.5–7 In addition, perfusion-weighted MRI (PWI) and diffusion-weighted MRI (DWI), including the apparent diffusion coefficient (ADC), may also be of value in diagnosing treatment-related changes after regorafenib initiation.8 Here, we report on ill-defining MR imaging findings of three patients with recurrent IDH-wild-type glioblastoma (age range, 43–63 years) treated with regorafenib, which are hitherto not well characterized and challenging to interpret. During treatment, all patients developed imaging correlates of an extensive necrosis with a contrast-enhancing rim on serial MRI. Besides the manifestation of the contrast-enhancing rim as a potential sign of tumor progression, restricted diffusion combined with partially low and decreasing ADC values suggested increased cellularity related to neoplastic tissue rather than necrosis. In contrast, the relative cerebral blood volume on PWI was equal to zero and markedly extensive photopenic defects on FET PET suggested treatment-related effects such as necrosis. In line with treatment-related effects, all three patients who developed these imaging findings showed a considerably longer post-progression overall survival (range, 7.8–27.3 months) after initiation of regorafenib. Discrepancies in MRI and FET PET prompted a stereotactic biopsy in one patient, revealing reactive changes consistent with coagulative necrosis lacking vital tumor cells (Figure 1). At last follow-up, this patient was still alive after 13.4 months and 10 cycles of regorafenib, whereas after initiation of regorafenib the other patients died after 7.8 and 27.3 months, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
- Department of Experimental Pediatric Oncology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Department of Stereotactic and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne,Germany.
- Institute of Neuropathology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
- Institure of Radiology, Division of Neuroradiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne,Germany.
ORCID-Profile: Jan-Michael Werner, Norbert Galldiks
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Werner, J. M., Wollring, M. M., Tscherpel, C., Rosen, E. K., Werr, L., Stetter, I., Rueß, D., Ruge, M. I., Brunn, A., Al Shughri, A., Kabbasch, C., Fink, G. R., Langen, K. J., & Galldiks, N. (2023). Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad051
Vancouver
Werner JM, Wollring MM, Tscherpel C, Rosen EK, Werr L, Stetter I, et al. Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad051
BibTeX
@article{Werner2023,
author = {Werner, Jan-Michael and Wollring, Michael M and Tscherpel, Caroline and Rosen, Elena K and Werr, Lisa and Stetter, Isabelle and Rueß, Daniel and Ruge, Maximilian I and Brunn, Anna and Al Shughri, Abdulkader and Kabbasch, Christoph and Fink, Gereon R and Langen, Karl-Josef and Galldiks, Norbert},
title = {Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noad051}
}
EUVIMED